Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer

Status No longer available

Clinical Trial Summary

This study provides compassionate use of bicalutamide (Casodex) at a 150-mg dose for subjects with prostate cancer prior to it becoming commercially available. The patient will receive bicalutamide 150-mg as long as the physician feels that the subject is benefiting from this therapy and safety information is provided regularly to AstraZeneca. Treatment will be discontinued after bicalutamide 150-mg becomes commercially available.

Clinical Trial Description

n/a

Study Design

N/A

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00636259
Study type	Expanded Access
Source	AstraZeneca
Contact
Status	No longer available
Phase	N/A

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02217709` - Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer	Phase 2
Completed	`NCT03077659` - Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer	Phase 2
Active, not recruiting	`NCT03624660` - Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer	N/A
Completed	`NCT01054079` - Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer	Phase 2
Terminated	`NCT00512668` - Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer	Phase 1
Completed	`NCT00087139` - Ixabepilone in Treating Patients With Metastatic Prostate Cancer	Phase 2
Completed	`NCT00182052` - Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer	Phase 3
Active, not recruiting	`NCT03511196` - Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer	Early Phase 1
Active, not recruiting	`NCT01655836` - High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer	Phase 1
Terminated	`NCT03535675` - Muscadine Plus (MPX) In Men With Prostate Cancer	Phase 3
Terminated	`NCT01866423` - Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	Phase 2
Completed	`NCT02234921` - Pilot Study of DRibble Vaccine for Prostate Cancer Patients	Phase 1
Completed	`NCT01468532` - Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03686683` - Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer	Phase 3
Active, not recruiting	`NCT03689699` - Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)	Phase 1/Phase 2
Recruiting	`NCT04694924` - Prospective Prostate Cancer and Patient-reported Outcomes Registry
Active, not recruiting	`NCT04909294` - Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma	N/A
Completed	`NCT02225925` - Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound	N/A
Completed	`NCT01949519` - Docetaxel and Lycopene in Metastatic Prostate Cancer	Phase 1
Completed	`NCT01433913` - Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery	Phase 2